This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthofix JuniOrtho Plating System Gets Regulatory Clearances
by Zacks Equity Research
Orthofix (OFIX) rides high on dual regulatory clearances for its deformity correction system, thus solidifying its pediatric orthopedics portfolio.
Orthofix (OFIX) Misses Q1 Earnings Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of -18.18% and 0.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Coronavirus Hits Elective Procedures: 3 MedTech Stocks to Avoid
by Trina Mukherjee
Amid the pandemonium on the account of coronavirus, we look into three stocks that have been struggling to cope with the scenario.
Orthofix Supports FDA Class III Label Continuation for BGS
by Zacks Equity Research
Orthofix (OFIX) pledges support for the continuation of the FDA's Class III status of BGS devices.
Orthofix (OFIX) Q4 Earnings Match Estimates, Margins Decline
by Zacks Equity Research
We are upbeat about the year-over-year revenue growth recorded by majority of Orthofix's (OFIX) key operating segments in Q4.
Orthofix (OFIX) Q4 Earnings Match Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 0.00% and -1.14%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of -21.15% and -4.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
3D Printing Gaining Popularity: 3 MedTech Stocks to Watch
by Trina Mukherjee
In the near future, there is a probability of 3D-printed implantable organs becoming a reality, thereby increasing the number of lives saved.
Orthofix Medical (OFIX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Orthofix Medical's (OFIX) Q2 performance across all business segments has been commendable, except for spinal implants.
Orthofix (OFIX) Q2 Earnings Miss Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of -30.00% and 0.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Orthofix (OFIX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will MedTech Ease Investors' Concern & Outperform? 4 Picks
by Urmimala Biswas
Lower investment in MedTech might prove to be a concern, more so as gains within this space are staggering.
Orthofix (OFIX) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of -32.50% and -1.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Reports Encouraging M6-C Disc Study Results
by Zacks Equity Research
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.
Orthofix (OFIX) Earnings Beat Estimates in Q4, Margins Fall
by Zacks Equity Research
Orthofix (OFIX) revenues across majority product lines witness year-over-year growth.
Analysts Estimate Orthofix (OFIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?
by Zacks Equity Research
Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
New Strong Buy Stocks for December 14th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Orthofix (OFIX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for October 31st
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
Orthofix (OFIX) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Orthofix (OFIX) delivered earnings and revenue surprises of 35.14% and 1.37%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Orthofix (OFIX) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Orthofix (OFIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today: